VIVUS Company Profile (NASDAQ:VVUS)


VIVUS logoVIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:VVUS
  • CUSIP: 92855110
  • Web:
  • Market Cap: $118.36 million
  • Outstanding Shares: 105,682,000
Average Prices:
  • 50 Day Moving Avg: $1.03
  • 200 Day Moving Avg: $1.14
  • 52 Week Range: $0.93 - $1.47
  • Trailing P/E Ratio: 3.27
  • Foreward P/E Ratio: -2.49
  • P/E Growth: -3.24
Sales & Book Value:
  • Annual Revenue: $135.95 million
  • Price / Sales: 0.87
  • Book Value: $0.17 per share
  • Price / Book: 6.59
  • EBIDTA: $68.49 million
  • Net Margins: -78.63%
  • Return on Assets: -16.44%
  • Debt-to-Equity Ratio: -6.03%
  • Current Ratio: 2.71%
  • Quick Ratio: 2.61%
  • Average Volume: 714,797 shs.
  • Beta: 1.29
  • Short Ratio: 10.69

Frequently Asked Questions for VIVUS (NASDAQ:VVUS)

What is VIVUS's stock symbol?

VIVUS trades on the NASDAQ under the ticker symbol "VVUS."

How were VIVUS's earnings last quarter?

VIVUS, Inc. (NASDAQ:VVUS) released its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.12. The firm had revenue of $27.01 million for the quarter. View VIVUS's Earnings History.

When will VIVUS make its next earnings announcement?

VIVUS is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for VIVUS.

Where is VIVUS's stock going? Where will VIVUS's stock price be in 2017?

1 brokerages have issued twelve-month price targets for VIVUS's stock. Their forecasts range from $2.80 to $2.80. On average, they anticipate VIVUS's stock price to reach $2.80 in the next year. View Analyst Ratings for VIVUS.

Who are some of VIVUS's key competitors?

Who owns VIVUS stock?

VIVUS's stock is owned by many different of institutional and retail investors. Top institutional investors include North Tide Capital LLC (8.52%), Renaissance Technologies LLC (5.86%), Credit Suisse AG (3.60%), Vanguard Group Inc. (3.35%), Sarissa Capital Management LP (2.44%) and Acadian Asset Management LLC (1.02%). Company insiders that own VIVUS stock include John L Slebir, North Tide Capital, Llc and Santosh T Varghese. View Institutional Ownership Trends for VIVUS.

Who sold VIVUS stock? Who is selling VIVUS stock?

VIVUS's stock was sold by a variety of institutional investors in the last quarter, including North Tide Capital LLC, Credit Suisse AG, KCG Holdings Inc., California Public Employees Retirement System and Menta Capital LLC. Company insiders that have sold VIVUS stock in the last year include North Tide Capital, Llc and Santosh T Varghese. View Insider Buying and Selling for VIVUS.

Who bought VIVUS stock? Who is buying VIVUS stock?

VIVUS's stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Acadian Asset Management LLC, Oxford Asset Management, Vanguard Group Inc., Nine Chapters Capital Management LLC, Geode Capital Management LLC, Morgan Stanley and Bank of New York Mellon Corp. View Insider Buying and Selling for VIVUS.

How do I buy VIVUS stock?

Shares of VIVUS can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of VIVUS stock cost?

One share of VIVUS stock can currently be purchased for approximately $1.12.

Analyst Ratings

Consensus Ratings for VIVUS (NASDAQ:VVUS) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.80 (150.00% upside)

Analysts' Ratings History for VIVUS (NASDAQ:VVUS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/25/2016WallachBeth CapitalSet Price TargetBuy$2.80N/AView Rating Details
5/4/2016JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
3/10/2016Needham & Company LLCReiterated RatingHoldN/AView Rating Details
2/29/2016Royal Bank of CanadaDowngradeOutperform -> Sector Perform$4.00 -> $1.00N/AView Rating Details
(Data available from 5/23/2015 forward)


Earnings History for VIVUS (NASDAQ:VVUS)
Earnings by Quarter for VIVUS (NASDAQ:VVUS)
Earnings History by Quarter for VIVUS (NASDAQ:VVUS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017Q1 2017($0.13)($0.01)$27.01 millionViewListenView Earnings Details
3/8/2017Q4 2016$0.23$0.54$48.82 million$81.81 millionViewListenView Earnings Details
11/9/2016Q316($0.19)($0.09)$21.91 million$13.40 millionViewListenView Earnings Details
8/4/2016Q216($0.31)($0.11)$19.00 million$13.77 millionViewN/AView Earnings Details
5/3/2016Q116($0.21)($0.12)$17.97 million$15.32 millionViewN/AView Earnings Details
3/9/2016Q4($0.12)($0.12)$22.90 million$15.34 millionViewN/AView Earnings Details
11/4/2015Q315($0.17)($0.15)$20.24 million$24.90 millionViewN/AView Earnings Details
7/30/2015Q215($0.23)($0.19)$18.76 million$23.00 millionViewListenView Earnings Details
5/5/2015Q115($0.22)($0.15)$21.80 million$32.20 millionViewN/AView Earnings Details
2/24/2015Q414($0.25)($0.25)$20.00 million$21.70 millionViewListenView Earnings Details
11/5/2014Q314($0.25)($0.10)$21.90 million$33.90 millionViewListenView Earnings Details
8/7/2014Q214($0.28)($0.25)$17.90 million$21.90 millionViewListenView Earnings Details
5/5/2014Q114($0.37)($0.15)$11.40 million$36.70 millionViewN/AView Earnings Details
2/24/2014Q413($0.40)($0.17)$28.20 million$44.06 millionViewListenView Earnings Details
11/5/2013Q313($0.38)($0.48)$21.78 million$27.38 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.44)($0.55)$12.76 million$5.53 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.51)($0.53)$5.22 million$4.10 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.44)($0.56)$3.09 million$1.97 millionViewN/AView Earnings Details
11/6/2012Q312($0.34)($0.40)$0.35 million$0.04 millionViewN/AView Earnings Details
8/7/2012($0.23)($0.24)ViewN/AView Earnings Details
5/7/2012($0.13)($0.20)ViewN/AView Earnings Details
2/28/2012($0.12)($0.14)ViewN/AView Earnings Details
11/7/2011($0.12)($0.10)ViewN/AView Earnings Details
8/1/2011($0.13)($0.20)ViewN/AView Earnings Details
5/2/2011($0.15)($0.12)ViewN/AView Earnings Details
2/28/2011($0.22)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for VIVUS (NASDAQ:VVUS)
Current Year EPS Consensus Estimate: $-0.39 EPS
Next Year EPS Consensus Estimate: $-0.45 EPS


Dividend History for VIVUS (NASDAQ:VVUS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for VIVUS (NASDAQ:VVUS)
Insider Ownership Percentage: 3.00%
Institutional Ownership Percentage: 34.82%
Insider Trades by Quarter for VIVUS (NASDAQ:VVUS)
Institutional Ownership by Quarter for VIVUS (NASDAQ:VVUS)
Insider Trades by Quarter for VIVUS (NASDAQ:VVUS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/4/2017Santosh T VargheseInsiderSell440$1.08$475.20View SEC Filing  
3/10/2017North Tide Capital, LlcMajor ShareholderSell1,149,400$1.16$1,333,304.00View SEC Filing  
3/7/2017North Tide Capital, LlcMajor ShareholderSell192,800$1.08$208,224.00View SEC Filing  
3/2/2017North Tide Capital, LlcMajor ShareholderSell160,100$1.13$180,913.00View SEC Filing  
2/27/2017North Tide Capital, LlcMajor ShareholderSell333,000$1.14$379,620.00View SEC Filing  
2/22/2017North Tide Capital, LlcMajor ShareholderSell161,800$1.11$179,598.00View SEC Filing  
2/16/2017North Tide Capital, LlcMajor ShareholderSell305,090$1.10$335,599.00View SEC Filing  
2/13/2017North Tide Capital, LlcMajor ShareholderSell176,410$1.11$195,815.10View SEC Filing  
2/8/2017North Tide Capital, LlcMajor ShareholderSell563,527$1.06$597,338.62View SEC Filing  
2/7/2017North Tide Capital, LlcMajor ShareholderSell6,200$1.11$6,882.00View SEC Filing  
2/6/2017North Tide Capital, LlcMajor ShareholderSell28,027$1.10$30,829.70View SEC Filing  
2/3/2017North Tide Capital, LlcMajor ShareholderSell78,633$1.12$88,068.96View SEC Filing  
1/28/2017Santosh T VargheseInsiderSell429$1.11$476.19View SEC Filing  
12/31/2016Santosh T VargheseInsiderSell13,790$1.12$15,444.80View SEC Filing  
10/1/2016Santosh T VargheseInsiderSell710$1.14$809.40View SEC Filing  
8/2/2016Santosh T VargheseInsiderSell12,559$1.07$13,438.13View SEC Filing  
7/1/2016Santosh T VargheseVPSell366$1.21$442.86View SEC Filing  
4/7/2016Santosh T VargheseInsiderSell329$1.65$542.85View SEC Filing  
4/1/2016North Tide Capital, LlcMajor ShareholderBuy2,160$1.40$3,024.00View SEC Filing  
3/31/2016North Tide Capital, LlcMajor ShareholderBuy383,300$1.29$494,457.00View SEC Filing  
3/28/2016North Tide Capital, LlcMajor ShareholderBuy202,000$1.12$226,240.00View SEC Filing  
3/16/2016North Tide Capital, LlcMajor ShareholderBuy500,000$1.21$605,000.00View SEC Filing  
1/1/2016John L SlebirSVPSell2,973$3.04$9,037.92View SEC Filing  
1/8/2015North Tide Capital, LlcMajor ShareholderBuy500,000$3.12$1,560,000.00View SEC Filing  
1/6/2015North Tide Capital, LlcMajor ShareholderBuy476,800$3.04$1,449,472.00View SEC Filing  
1/2/2015North Tide Capital, LlcMajor ShareholderBuy523,200$2.90$1,517,280.00View SEC Filing  
3/11/2014Seth H.Z. FischerCEOBuy3,080$6.07$18,695.60View SEC Filing  
11/11/2013Alexander DennerDirectorBuy566,844$8.59$4,869,189.96View SEC Filing  
9/5/2013Timothy E MorrisCFOSell10,654$11.95$127,315.30View SEC Filing  
9/4/2013Michael J AstrueDirectorBuy10,000$11.96$119,600.00View SEC Filing  
6/27/2013Jon C BiroInsiderBuy2,000$12.85$25,700.00View SEC Filing  
5/29/2013Ernest MarioDirectorBuy15,000$14.68$220,200.00View SEC Filing  
8/20/2012Ernest MarioDirectorBuy5,000$20.75$103,750.00View SEC Filing  
8/10/2012Ernest MarioDirectorBuy20,000$21.74$434,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for VIVUS (NASDAQ:VVUS)
Latest Headlines for VIVUS (NASDAQ:VVUS)
DateHeadline logoAstrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab - May 22 at 7:38 PM logoShire (SHPG) Up on Positive Phase III Study Data on HAE Drug - May 19 at 6:44 PM logoZacks: Analysts Anticipate VIVUS, Inc. (VVUS) Will Post Earnings of -$0.13 Per Share - May 11 at 9:07 AM logoVIVUS (VVUS) Loss Narrower than Expected, Revenues Up Y/Y - Yahoo Finance - May 6 at 3:32 PM logoVIVUS, Inc. (VVUS) - May 6 at 1:29 AM logoVIVUS, Inc. (VVUS) Posts Earnings Results, Beats Estimates By $0.12 EPS - May 4 at 10:10 PM logoEdited Transcript of VVUS earnings conference call or presentation 3-May-17 8:30pm GMT - May 4 at 9:45 AM logoVivus' (VVUS) CEO Seth Fischer on Q1 2017 Results - Earnings Call Transcript - May 3 at 11:55 PM logoVIVUS Reports 2017 First Quarter Financial Results - May 3 at 6:54 PM logoVivus reports 1Q loss - May 3 at 6:54 PM logoInvestor Network: VIVUS, Inc. to Host Earnings Call - May 3 at 9:49 AM logoVIVUS (VVUS) Receiving Positive Press Coverage, Report Finds - May 2 at 1:18 PM logoVIVUS, Inc. (VVUS) to Release Earnings on Wednesday - May 1 at 5:02 PM logoVIVUS (VVUS) Earns Media Impact Score of 0.13 - April 26 at 8:28 AM logoVIVUS Announces Date of 2017 First Quarter Business Update and Financial Results Teleconference - April 25 at 8:19 AM logoVIVUS (VVUS) Receiving Positive News Coverage, Study Finds - April 22 at 10:51 AM logo-$0.13 Earnings Per Share Expected for VIVUS, Inc. (VVUS) This Quarter - April 20 at 1:07 PM logoVIVUS (VVUS) Getting Somewhat Positive Press Coverage, Study Finds - April 19 at 9:16 AM logoVIVUS (VVUS) Earns News Sentiment Rating of 0.04 - April 16 at 9:51 AM logoVIVUS, Inc. (VVUS) Short Interest Update - April 15 at 5:56 PM logoVIVUS (VVUS) Down 14.1% Since Earnings Report: Can It Rebound? - Nasdaq - April 10 at 8:24 AM logoVIVUS (VVUS) Down 14.1% Since Earnings Report: Can It Rebound? - April 10 at 8:24 AM logoOrexigen Releases Q4 Results, Vivus Reacquires Stendra from Sanofi - March 30 at 3:21 PM logoVivus Inc. stock rises 4.6% after regaining certain commercial rights for Stendra from Sanofi - MarketWatch - March 28 at 8:19 AM logoVIVUS In Deal To Reacquire STENDRA Commercial Rights From Sanofi - March 27 at 7:53 PM logoVIVUS In Deal To Reacquire STENDRA Commercial Rights From Sanofi - Quick Facts - March 27 at 7:53 PM logoVIVUS, Inc. Reacquires STENDRA(R) (Avanafil) Commercial Rights from Sanofi - March 27 at 7:53 PM logo8:32 am Vivus reaches an agreement w/ Sanofi (SNY) for Sanofi to return the commercial rights for STENDRA in Africa, the Middle East, Turkey and Russia to the co; terms not disclosed - March 27 at 7:53 PM logoVIVUS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Sta - March 27 at 7:53 PM logoVIVUS, Inc. :VVUS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017 - March 16 at 6:43 AM logoVIVUS INC Financials - March 14 at 8:15 PM logoNorth Tide Capital, Llc Sells 1,149,400 Shares of VIVUS, Inc. (VVUS) Stock - March 10 at 6:18 PM logoMid-Morning Market Update: Markets Edge Higher; Staples Earnings Miss Views - March 10 at 12:21 AM logoEdited Transcript of VVUS earnings conference call or presentation 8-Mar-17 9:30pm GMT - March 10 at 12:21 AM logoVIVUS, Inc. (VVUS) Announces Earnings Results, Beats Estimates By $0.31 EPS - March 9 at 12:21 PM logoVivus' (VVUS) CEO Seth Fischer on Q4 2016 Results - Earnings Call Transcript - March 9 at 4:32 AM logoVIVUS INC Files SEC form 10-K, Annual Report - March 9 at 4:32 AM logoVIVUS Reports Fourth Quarter and Full Year 2016 Financial Results - March 9 at 4:32 AM logoVIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - March 9 at 4:32 AM logoQ4 2016 VIVUS Inc Earnings Release - After Market Close - March 8 at 8:41 AM logoVIVUS Announces Date of 2016 Fourth Quarter Business Update and Financial Results Teleconference - February 28 at 8:38 AM logoBiotech's Rally Shows No Signs of Slowing Down: Today's Reports on Eyegate Pharmaceuticals and VIVUS - February 22 at 11:10 AM logoVIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers - January 17 at 8:52 PM logoVIVUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - January 10 at 4:05 PM logoVIVUS (VVUS) Acquires Tacrolimus and Ascomycin Rights from Selten Pharma for PAH - - January 10 at 1:59 AM logoVIVUS INC Files SEC form 8-K, Other Events - January 9 at 8:57 PM logoVIVUS (VVUS) Acquires Tacrolimus and Ascomycin Rights from Selten Pharma for PAH - January 9 at 3:55 PM logoVIVUS and Selten Pharma Announce Agreement for the Development and Commercialization Rights to Treatments for Pulmonary Arterial Hypertension (PAH) - January 9 at 3:55 PM logo9:01 am Vivus acquires Selten Pharma's rights for the development and commercialization of tacrolimus and ascomycin for the treatment of Pulmonary Arterial Hypertension and related vascular diseases; terms not disclosed - January 9 at 3:55 PM logoVIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Stateme - January 9 at 3:55 PM



VIVUS (VVUS) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by Staff